Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.57 |
| ▸ | GRK5 | P34947 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679113 | 0.88 | FYN (0.68) | FYNGRK5CSF1RDAPK1MAPK8 | |
| SCHEMBL1679460 | 0.86 | FYN (0.58) | FYNGRK5CSF1RDAPK1 | |
| SCHEMBL1679228 | 0.83 | FYN (0.58) | FYNGRK5CSF1RERN1BRAF | |
| SCHEMBL1679707 | 0.82 | FYN (0.63) | FYNCSF1RERN1BRAF | |
| SCHEMBL1679204 | 0.82 | FYN (0.63) | FYNCSF1RERN1BRAF | |
| SCHEMBL12734489 | 0.81 | FYN (0.64) | FYNCSF1RBRAF | |
| SCHEMBL1679065 | 0.81 | FYN (0.64) | FYNCSF1RERN1 | |
| SCHEMBL1679473 | 0.79 | GRK5 (0.64) | FYNGRK5DAPK1 | |
| SCHEMBL1679756 | 0.79 | ROCK2 (0.55) | FYNCSF1RERN1PTK2 | |
| SCHEMBL28141786 | 0.78 | IARS1 (0.60) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | FYN 1665/4885GRK5 827/4885KISS1R 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.